Multiple Sclerosis (MS) presents complex medical, emotional, and social challenges for individuals and communities. Across the healthcare ecosystem, a growing number of organizations are stepping up to make a difference through research, advocacy, access to care, and patient support. The following changemakers are united by a shared mission: to improve outcomes, empower lives, and create a more equitable future for those affected by MS. 

 MSSI: From Grassroots Care to National Policy Impact 

The Multiple Sclerosis Society of India (MSSI), established in 1985, is a registered non-profit organization dedicated to supporting Persons with Multiple Sclerosis (PwMS), their caregivers, and families. With nine active chapters across India and over 3,000 registered members, MSSI operates at two levels. At the central level, it advocates for inclusive policies for PwMS through strategic campaigns and policy recommendations submitted to ministries like the MoH&FW, MoF, MoSJ&E, and ICMR. These interventions have been well received both nationally and internationally. 

Among its key national advocacy efforts, ReassessMS addressed gaps in disability assessments that overlooked invisible symptoms like fatigue and cognitive issues. Following the campaign, the government issued revised guidelines in March 2024. The Numbers Matter campaign highlighted the lack of MS prevalence data in India, prompting the ICMR to launch the National MS Registry. Another ongoing initiative, InsureMyMS, advocates for inclusive insurance coverage for MS patients and is backed by a forthcoming white paper aimed at transforming India’s health insurance landscape. 

At the regional level, MSSI provides a wide spectrum of services: home nursing care and physiotherapy, free medical camps, and medicine reimbursements for underprivileged members. During the pandemic, MSSI ensured access through online doctor consultations. To support daily living, the organization distributes mobility aids like wheelchairs and walkers, along with comfort and hygiene products such as diapers, catheters, and commode chairs. It also organizes yoga sessions to promote physical and mental well-being and offers counselling support to help patients and caregivers manage the emotional toll of MS. Additionally, scholarships are provided to children of MS patients and financially struggling families to ensure uninterrupted education. 

Through these sustained efforts, MSSI continues to make a transformative impact on the lives of people affected by MS across India. 

Swarga Foundation: Redefining MS Care and Accessibility in India 

Founded in 2014 by Swarnalatha J, an MS warrior herself, Swarga Foundation has emerged as a national force in the Multiple Sclerosis (MS) space, seamlessly combining compassion with innovation. Based in Coimbatore, the foundation has touched the lives of over 10 crore people globally through transformative initiatives in accessibility, rehabilitation, advocacy, and outreach. 

At the core of its MS support efforts is the Sowkhya Pain Rehab Clinic, a one-of-a-kind center offering free neuro-rehabilitation in partnership with the Coimbatore Municipal Corporation. This initiative is further strengthened by a pioneering home care program run in collaboration with Pallium India, bringing physiotherapy, counseling, and medical aid directly to bedridden patients, ensuring they receive care in the comfort of their homes. 

Swarga’s commitment to accessibility led to the launch of Sarathi, Tamil Nadu’s first wheelchair-accessible cab service, empowering persons with disabilities with greater independence and mobility. The foundation’s advocacy has also driven accessibility redesigns in public infrastructure, including railway stations and police departments. 

Their large-scale awareness campaigns have educated over 1 crore people, fostering early diagnosis and reducing stigma associated with MS and other neurological conditions. In addition, Swarga Foundation extends support through assistive devices and financial aid for MS treatment, making a tangible difference in the lives of those affected. 

With a remarkable record of over 100 awards, including prestigious honors from the President and Governor of India, Swarga Foundation continues to be a beacon of inclusive healthcare and social change, championing the rights, dignity, and well-being of every individual living with MS. 

Bajaj Allianz: Securing the Future for MS Patients with Inclusive Insurance 

Bajaj Allianz General Insurance is making significant strides in advancing equity, access, and empowerment for individuals living with Multiple Sclerosis (MS) by offering comprehensive coverage through both its indemnity and critical illness products. In a country where healthcare costs can be overwhelming, this support is a critical lifeline for MS patients and their families. 

Through its flagship Criti Care – Critical Illness Insurance Policy, Bajaj Allianz covers MS among 43 critical illnesses, offering a lump-sum payout upon diagnosis—with no hospitalization requirement. This enables patients to access specialized treatments, therapies, and long-term care without the burden of immediate financial strain. With sum insured options ranging from ₹1 lakh to ₹50 lakhs for individuals aged 18 to 65, and lifetime renewability, the policy is designed to address both the immediate and evolving financial needs of diverse age groups. 

Further strengthening its MS coverage, Bajaj Allianz includes the condition in its Health Guard Policy, which provides hospitalization benefits, and its Global Health Care Policy, which extends access to international treatments. Together, these offerings ensure comprehensive protection—from diagnosis to global care—across various stages of MS management. 

By integrating Multiple Sclerosis into its mainstream insurance portfolio, Bajaj Allianz demonstrates a deep commitment to inclusive healthcare. These efforts reduce financial barriers, promote timely interventions, and empower patients to manage the condition with dignity and confidence. In doing so, the company plays a crucial role in advancing MS inclusion and reshaping India’s insurance landscape for chronic and neurological conditions. 

TATA AIG: Strengthening the Financial Shield for MS in India 

TATA AIG General Insurance is playing a pivotal role in reshaping access to healthcare for individuals living with Multiple Sclerosis (MS)—a complex neurological condition affecting over 2 lakh people in India, primarily between the ages of 20 and 50, the most productive years of life. Guided by a commitment to affordability, dignity, and protection, TATA AIG is developing thoughtfully tailored insurance products that address the unique medical and financial needs of this community. 

Among its offerings, the MediCare Premier plan stands out for its high sum insured options of up to ₹3 crore, addressing the substantial treatment costs associated with chronic neurological illnesses. This policy includes a Restore Benefit, cash support during prolonged hospitalization, coverage for advanced diagnostics like PET-CT and MRI, and even emergency air ambulance services. The plan further extends global coverage for planned hospitalization, recognizing the growing demand for specialized international treatment. 

Recognizing the devastating impact of critical illness expenses, TATA AIG’s MediCare Select introduces the Infinite Advantage feature, which allows unlimited coverage for a single claim during the policy lifetime, removing caps on treatment costs when it matters most. Additionally, customizable riders such as OPD Care, psychological therapy, and international second opinions ensure holistic and adaptable protection. 

For those seeking benefit-based plans, Criti Medicare offers a lump-sum payout upon MS diagnosis, along with waiver of premium and routine health check-ups, supporting patients throughout their journey with compassion and security. 

Evolving its underwriting practices to be more inclusive of individuals with pre-existing neurological conditions, TATA AIG is committed to advancing equity in healthcare access. On World MS Day, the company reaffirms its mission to raise awareness, amplify patient voices, and build insurance solutions that empower every Indian living with MS to move forward with confidence and care. 

Roche: Advancing Hope and High-Efficacy Solutions for MS Patients in India 

Roche is dedicated to addressing the unmet needs of Multiple Sclerosis (MS) patients in India, establishing itself as a trusted partner in navigating the complexities of this challenging neurological condition. The landmark launch of Ocrevus (Ocrelizumab) in India in 2024 marks a transformative step in MS management, offering renewed hope to those living with the unpredictable symptoms of MS. As Roche’s flagship and blockbuster molecule worldwide, Ocrevus stands out as the only monoclonal antibody drug approved for both Relapsing Remitting MS and Primary Progressive MS, backed by over 10 years of robust clinical and real-world evidence. 

Globally, Ocrevus has treated over 400,000 patients, with more than 350 patients in India benefiting since its launch. Its proven efficacy in significantly slowing disability progression across the MS spectrum offers patients the promise of a near-normal life when started early with safe, high-efficacy, disease-modifying therapies. 

Beyond pharmaceutical innovation, Roche actively contributes to building a stronger MS care ecosystem in India. Through strategic partnerships with the Multiple Sclerosis Society of India (MSSI) and collaborations with government bodies, Roche supports efforts to improve healthcare provider capacity for early screening and diagnosis. The company also advocates for fair and comprehensive insurance coverage and a more inclusive recognition of disability benefits, aiming to empower MS patients toward fuller, more independent lives. 

Roche’s holistic commitment amplifies awareness, promotes timely intervention, and drives access to advanced therapies, reinforcing its mission to transform the journey of MS patients across India. 

Disclaimer: 
“Voices for Multiple Sclerosis: United Organizations Advancing Equity, Access & Empowerment” is intended for informational purposes only and does not constitute endorsement or ranking. Many other organizations are doing excellent work in this segment beyond those listed here. The order or inclusion of organizations in this list does not signify any ranking or preference. Readers are encouraged to explore further for comprehensive insights. 

Introduction:

Behind every life saved, every outbreak prevented, and every community protected, tireless innovators are working to make vaccines safer, faster, and more accessible. "Guardians of Global Health: Leading Vaccine Innovators of 2025" shines a spotlight on the organizations rewriting the future of healthcare. These changemakers aren't just producing vaccines — they are building hope, bridging gaps, and turning scientific breakthroughs into real-world impact. Join us to celebrate the vision, passion, and resilience driving global immunization forward.

Serum Institute of India: Powering Global Immunization Through Innovation and Impact

As the world’s largest vaccine manufacturer by volume, the Serum Institute of India Pvt. Ltd. (SII) is a cornerstone of global public health. Producing nearly 1.9 billion doses annually, SII’s vaccines touch the lives of children and adults in over 170 countries, with an estimated 65% of the world’s children receiving at least one SII-manufactured vaccine.

Founded in 1966, SIIPL's primary mission is to produce life-saving immunobiological drugs, with a particular emphasis on affordability and accessibility. Guided by a strong commitment to improving global health, the company has played a pivotal role in reducing the prices of essential vaccines, such as Diphtheria, Tetanus, Pertussis, HIB, BCG, r-Hepatitis B, Measles, Mumps, and Rubella. Notably, they are the manufacturers of 'Pneumosiil,' the world's most affordable PCV, 'Cervavac' the first indigenous qHPV vaccine in India, and R21/Matrix-M™, the second Malaria vaccine to be authorized for use in children in malaria-endemic regions, ‘MenFive’, the first in the world Pentavalent (ACYWX) Meningococcal Polysaccharide Conjugate Vaccine, approved and WHO-prequalified for use in the paediatric population. Moreover, SIIPL has been at the forefront of the global fight against COVID-19, delivering over 2 billion doses of the COVID-19 vaccine worldwide.

Underpinned by a strong philanthropic ethos, SII continues to bridge immunization gaps worldwide, particularly among underserved populations. Driven by purpose and backed by science, the Serum Institute of India continues to shape a healthier future—one vaccine, one life, one community at a time.

AstraZeneca: Advancing Global Immunization Through Innovation and Collaboration

In celebration of World Immunization Week, AstraZeneca reaffirms its ambition to innovate and deliver transformative vaccines and antibodies that provide long-lasting immunity where the disease burden is greatest. The company’s response to the COVID-19 pandemic demonstrated its capability to address significant global health challenges.

AstraZeneca remains committed to ensuring that no patient is left behind by optimizing the potential of vaccines and immune therapies. It is actively developing next-generation vaccines designed for robust, long-lasting immune responses and pioneering long-acting antibodies using advanced technologies, targeting key pathogens such as influenza.

The company’s commitment extends beyond addressing immediate health concerns, with a vision to reshape future health landscapes through strategic partnerships and collaborative innovation. These partnerships play a vital role in advancing public health and transforming scientific breakthroughs into meaningful health outcomes.

In India, AstraZeneca’s educational initiatives and collaborations are empowering healthcare professionals and patients alike, reflecting its ambition to build a healthier, more resilient future. Through its dedication to scientific excellence and partnership, AstraZeneca continues to strive toward transforming public health and creating a lasting impact for communities worldwide.

Bharat Biotech: Achieving a Milestone in Vaccine Development with Typbar TCV®

Immunisation for all is humanly possible. Global partnerships, such as Gavi and WHO’s Immunization Agenda 2030, demonstrate that when nations unite, even the most vulnerable populations can be vaccinated. By addressing global health challenges with affordable, high-quality vaccines, Bharat Biotech continues to strengthen public health infrastructure worldwide. Typbar TCV® is a testament to its innovation, saving lives and setting new benchmarks in vaccine development.

Bharat Biotech, a pioneering Indian biotechnology company, has significantly advanced global health with its innovative vaccines. One of its standout achievements is Typbar TCV®, the world’s first Typhoid Conjugate Vaccine (TCV), prequalified by the World Health Organization (WHO). Evaluated in Human Challenge Studies at Oxford University, Typbar TCV® demonstrated 100% immunogenicity and prevents up to 87.1% of infections, based on real-life definitions. This Vaccine offers long-lasting immunity against typhoid fever, a life-threatening disease affecting millions, particularly children in developing nations. Unlike traditional vaccines, Typbar TCV® is effective in infants as young as six months and provides robust protection with a single dose, helping combat antimicrobial-resistant typhoid strains.  

Bharat Biotech’s commitment to cutting-edge research extends beyond Typbar TCV®. The company played a crucial role during the COVID-19 pandemic by developing COVAXIN, India’s first indigenous vaccine and the world’s first Intranasal COVID-19 vaccine, iNCOVACC. With a portfolio spanning Polio, Rotavirus, Japanese Encephalitis, Rabies, Zika, Chikungunya, Cholera, and Malaria vaccines, Bharat Biotech exemplifies "Make in India" excellence in biotechnology.  

Pfizer: Advancing Adult Immunization Through Innovation and Impact
 

With a legacy spanning over 170 years, Pfizer remains one of the world’s leading pharmaceutical companies, powered by science and innovation. In India, Pfizer Limited delivers expert therapies across four core business categories: Vaccines, Hospitals, Internal Medicine, and Inflammation & Immunology. As a pioneer in vaccine development, Pfizer has introduced groundbreaking solutions such as Comirnaty® (COVID-19 vaccine), Prevnar 13® (Pneumococcal vaccine), and Trumenba® (Meningococcal vaccine), reinforcing its commitment to addressing global health challenges through a research-driven approach.

Pfizer’s high-quality vaccines are designed to make a meaningful impact at every stage of life, helping protect as many individuals as possible from life-threatening diseases. Driven by a passion for science, a commitment to excellence, and a strong focus on public health, Pfizer continues to lead bold advancements in research, development, and world-class manufacturing. This passion shapes every breakthrough and defines the company's purpose.

In India, Pfizer has collaborated with several leading hospitals to establish Centres of Excellence (CoEs) dedicated to advancing patient care through comprehensive adult vaccination programs. These centers focus on protecting against various vaccine-preventable diseases, including Pneumococcal disease, Influenza, Human Papillomavirus (HPV), and Hepatitis A and B.

With nearly 95% of deaths from vaccine-preventable diseases occurring among adults in India, the importance of adult vaccination cannot be overstated. Despite strong scientific evidence supporting adult immunization to enhance quality of life, awareness and adoption rates remain low. Pfizer’s CoEs aim to bridge this gap by empowering healthcare professionals with the knowledge and tools needed to advocate for timely adult immunization, particularly for individuals with chronic conditions such as COPD, asthma, diabetes, heart or kidney disease, and other immunocompromising conditions. Individuals with risk factors such as smoking, exposure to high pollution levels, or those aged 50 and above, are also encouraged to consult healthcare providers about vaccination as an essential preventive health measure.

Every day, Pfizer remains committed to creating a healthier world by inventing, developing, and championing vaccines that offer vital health benefits across all stages of life.

Panacea Biotec: Shaping the Future of Immunization and Healthcare Innovation
 

Panacea Biotec is an innovation-led, integrated biopharmaceutical group committed to the discovery, development, and commercialization of high-quality pharmaceuticals, vaccines, nutrition, and wellness products. The company blends cutting-edge science with a mission to address unmet medical needs through affordable solutions. With over 1,500 patents filed globally, Panacea Biotec has been recognized as a Thomson Reuters Top 50 Innovator of the Year in 2015 and 2016.

Panacea Biotec has played a pivotal role in the eradication of polio in India, delivering more than 10 billion doses of oral polio vaccines. Anticipating stagnation in polio eradication efforts in the early 2000s, the company developed and launched the world’s first monovalent and bivalent oral polio vaccines, contributing significantly to India achieving zero polio cases in 2011. This success laid the foundation for an even broader impact across infectious disease prevention.

In 2005, Panacea Biotec became the first company to develop a fully-liquid pentavalent vaccine (DTwP+HepB+Hib), branded as EasyFive-TT. Continuing its legacy of firsts, in 2017, Panacea Biotec introduced EasySix, the world’s first fully-liquid wP-IPV-based hexavalent vaccine (DTwP+HepB+Hib+IPV). To date, the company has supplied over 200 million doses of its innovative, fully-liquid vaccines worldwide.

The company's key vaccine offerings include EasyFour®-TT (DTwP+Hib), EasyFour®-Pol (DTwP+IPV), the bivalent oral polio vaccine (type-1 and type-3), and thiomersal-free Td (tetanus reduced diphtheria) vaccine. Panacea Biotec's pipeline features promising products such as NucoVac-11® (Pneumococcal Conjugate Vaccine) and DengiALL® (Recombinant Tetravalent Dengue Candidate Vaccine).

Beyond vaccines, Panacea Biotec's nutritional product portfolio supports holistic growth and development for children through offerings like ChilRun Full, ChilRun Full No Sucrose, and ChilRun 7+. Under the NikoMom brand, the company has introduced safe, natural, and non-toxic baby care products, including baby diapers and 99.9% water-based wet wipes for newborns.

Panacea Biotec has also commercialized its first New Chemical Entity (NCE), Sitcom (euphorbia prostate extract), for the treatment of piles following ICH guidelines, and launched PacliAll, the world’s first nanotechnology-based bioequivalent generic to Abraxane. With a robust research pipeline focused on high-barrier generics and advanced drug delivery systems such as nanoparticles, liposomes, and gastro-retentive platforms, Panacea Biotec continues to drive innovation at the intersection of science, technology, and healthcare accessibility.

The company remains steadfast in its mission to merge advanced science with a deep commitment to affordability, ensuring that healthcare solutions are accessible to all.

BRIC-National Institute of Immunology: Advancing Interdisciplinary Research to Tackle Global Health Challenges

The National Institute of Immunology (NII) is one of the foremost institutions under the Biotechnology Research and Innovation Council of the Department of Biotechnology, Government of India, dedicated to conducting cutting-edge research in immunology and allied sciences. Our mission is to advance the understanding of the immune system through cutting-edge interdisciplinary research. We aim to integrate diverse biological sciences— including immunology, infectious and chronic disease biology, molecular and cellular biology, chemical biology, structural biology, and computational biology—to develop innovative diagnostics, treatments, and vaccines. Our current initiatives address pressing global health challenges, such as emerging infectious diseases, tuberculosis, malaria, cancer, neurodegenerative and metabolic disorders. By fostering collaboration across these interconnected fields, NII is committed to promoting human health and developing effective strategies to combat diseases that significantly impact communities worldwide.

Abbott Strengthens Immunization Efforts with Advanced Vaccines for Children and Adults 

Abbott is dedicated to helping people stay healthy through scientifically developed vaccines that protect against infections such as Influenza, Typhoid, Hepatitis A, Japanese Encephalitis, and Pneumococcal diseases.

Dr. Jejoe Karankumar, Medical Director, Abbott India, stated, “At Abbott, we're dedicated to helping people stay healthy. Our scientifically developed vaccines help protect against infections like Influenza, Typhoid, Hepatitis A, Japanese Encephalitis, and Pneumococcal diseases.”

The company’s influenza vaccine is designed to offer immune protection and help the body build a strong defense against infections. Approved for use in individuals above six months of age, the vaccine supports public health by reducing infection risks. Abbott also collaborates with healthcare professionals to raise awareness about flu prevention and educate at-risk adults on vaccinations, ultimately helping to ease the burden on healthcare systems.

The Pneumococcal Conjugate Vaccine (PCV-14) is the latest addition to Abbott’s vaccine portfolio. It offers broad protection for children as young as six weeks old against 14 different strains of pneumococcal bacteria—representing the highest number of strains covered in a vaccine of its kind. By reducing the risk of severe infections like pneumonia and meningitis, particularly in children under two, PCV-14 supports healthier childhoods. This addition underscores the company’s commitment to providing lasting healthcare solutions that drive better health outcomes for children.

MSD Champions Cervical Cancer Awareness Through Vaccination and Strategic Partnerships

Vaccines play a critical and enduring role in global public health, helping to prevent a variety of infectious diseases. For more than 100 years, MSD has been a pioneer in the fight against certain vaccine-preventable diseases. In India, the company is dedicated to raising awareness about vaccine-preventable diseases, including cervical cancer. Over the years, MSD has partnered with more than 100 influencers and key opinion leaders (KOLs) to raise awareness about cervical cancer prevention. MSD is collaborating with organizations like FOGSI, AICC RCOG, and Femina Miss India to educate women and their families on preventive measures against cervical cancer. Additionally, MSD’s collaboration with the Delhi Capitals women’s cricket team leveraged the influence of sports to promote cervical cancer prevention. By fostering these partnerships and initiatives, MSD is committed to empowering communities and improving public health outcomes. MSD also collaborates with healthcare organizations, community groups, and policymakers to advocate for actions that will reduce the burden of cervical cancer in the country.
 

Bharat Serums and Vaccines Ltd: Innovating Life-Saving Treatments for Global Health Challenges 

Bharat Serums and Vaccines Ltd (BSV) (A Mankind Group Company) is one of the fastest-growing bio-pharmaceutical company in India, focusing on Women’s Health, IUI-IVF, and Critical Care & Emergency Medicine. Driven by people and science, BSV has pioneered a range of biological, biotech, and pharmaceutical products, offering innovative treatments that address unmet medical needs such as Rh Sensitization, Postpartum Hemorrhage, Endometriosis, Aplastic Anemia, and Bite Management (Snakebite, Dog bite). Today, with a strong presence in India and over 70+ countries, BSV continues to inspire, innovate, and improve the lives of millions of patients globally.

BSV’s Anti Rh(o)-D Immunoglobulin, winner of the Modi Prix Galien 2024 (Best Biotechnology Product), is the world’s first marketed recombinant that addresses RH incompatibility in Rh negative mothers preventing complications of haemolytic disease in newborn babies. Since its launch in 2021, Anti Rh(o)-D has protected over 2.6 million Rh-negative mothers. One of BSV’s flagship products, Anti-Snake Venom Serum (ASVS), remains the appropriate treatment to be administered for snakebites and ultimately save lives. ASVS has saved over 1 million lives in the last 20+ years. Committed to innovating in India, for India and the world, BSV continues to build a healthier India and a healthier world.

Disclaimer:
“Guardians of Global Health: Leading Vaccine Innovators of 2025” highlights organizations making notable contributions to vaccine manufacturing and global health. This list is for informational purposes only and does not imply endorsement or ranking. Readers are encouraged to explore further for detailed information.

 

In a world where medical marvels often make headlines, it’s easy to overlook the quiet power of a vaccine. At Sree Uthradom Thirunal (SUT) Hospital, Pattom, immunization is more than a calendar event—it is a powerful act of protection, a social responsibility, and a commitment to health equity.

As the world observes World Immunization Week 2025 (April 24–30), SUT Pattom steps forward—not merely to catch up on missed vaccines, but to lead a meaningful conversation about what it truly means to prevent disease in today’s healthcare landscape.

“This year, the hospital is focusing on something deeper than numbers and doses—connection. From the maternity ward to every corner of its care network, SUT Pattom is amplifying the message that immunization is not a formality—it’s a promise. A promise that no child will suffer from a preventable disease. A promise that elderly patients can live safely among loved ones. A promise that no frontline worker faces risk without protection.”

At the center of this commitment is SUT Pattom’s dedicated Immunization Clinic, which offers a wide spectrum of vaccines, including HPV for women, seasonal influenza, pneumococcal vaccines for high-risk groups, and COVID-19 booster shots in line with recommendations as applicable during the critical period. For patients with chronic conditions, such as those on dialysis, customized vaccination schedules are a standard part of care, highlighting the hospital’s patient-specific, holistic approach to prevention.

“The vaccination camps organized during this week are not just routine activities; they are carefully curated moments of trust. Whether it’s a child receiving their first vaccine or a senior citizen being counseled about adult immunizations, each interaction is handled with empathy and clarity. Even within its workforce, SUT Pattom has implemented an internal booster campaign, reflecting its belief that care begins at home. ”

Further extending its impact is the hospital’s Health & Wellness YouTube channel—a digital platform bridging medical knowledge and public awareness. Through accessible, multilingual content, clinicians from SUT Pattom simplify complex topics such as vaccine schedules, myths, adult vaccination needs, and recent updates, making healthcare education available at the community’s fingertips.

Behind the scenes, it is the dedicated immunization clinic nurses who ensure that no patient is left behind by tracking due vaccines and scheduling follow-ups. At SUT Pattom, it’s not just about giving a shot—it’s about building continuity, trust, and a sense of shared responsibility in every encounter.

What sets the hospital apart is not just the services it provides, but how it delivers them. Rather than large-scale campaigns, the focus is on personal, compassionate conversations at the point of care. A doctor reassuring a hesitant parent. A nurse explaining vaccine options to a dialysis patient. These micro-moments of understanding are what truly transform healthcare.

SUT Pattom firmly believes healthcare should be human and preventive. As it marks World Immunization Week 2025, the hospital reaffirms its promise: that the smallest needle can carry the biggest hope—and every vaccine administered is a step toward a healthier, safer tomorrow.

Tuberculosis remains one of the world's deadliest infectious diseases, demanding relentless innovation and collaboration. "Champions of Change: Organizations Pioneering the Fight Against Tuberculosis" highlights the key players leading the charge against TB—driving breakthroughs in diagnostics, treatment, and prevention. From cutting-edge research to community-based interventions, these organizations are shaping a future free from TB and bringing us closer to eradication.

Mylab Discovery Solutions – Pioneering Indigenous TB Diagnostics

Mylab Discovery Solutions aims to help eliminate TB in India through innovative diagnostic solutions. They developed the PathoDetect kit, India's first indigenous TB detection kit which identifies TB and drug resistance to Rifampicin and Isoniazid in a single test. This RT-PCR-based kit works with Mylab Compact devices for automated testing, processing 8 or more samples in around two hours.

Additionally, Mylab offers the Cy-TB, the next-generation latent TB detection test, launched in partnership with the Serum Institute of India. The test has been recommended for use by the Expert Review Panel (ERP) of the Global Fund.

Further, Mylab introduced MyBeam, a handheld X-ray device designed to facilitate screening in remote and hard-to-reach areas.

These tests enhance TB diagnosis, treatment, and prevention, facilitating early detection and appropriate treatment. Mylab is committed to making TB testing accessible, accurate, and cost-effective.

Molbio Diagnostics – Revolutionizing Rapid TB Testing

Molbio Diagnostics aims to revolutionize healthcare by providing cutting edge, gold standard point-of-care diagnostic solutions,  at the point of care. Their flagship product, the Truenat Real-Time Quantitative micro PCR system, a multi-disease platform enables rapid and accurate TB testing in various settings, including remote areas. This technology decentralizes diagnostics, ensuring early diagnosis and timely treatment initiation.

In its mission to offer a complete end-to-end solution for TB care, Molbio in 2023, added ProRad Atlas, an AI-powered handheld ultra-portable X-ray to its basket of solutions.  Fit for use without any infrastructure, ProRad Atlas can be carried by a technician on a backpack to the last mile and used for mass screening for TB at the community level. This can be followed by a confirmatory test on Truenat. In 2024-2025, Molbio will continue to expand its impact by rolling out other Truenat across the world, enabling governments and treatment providers to fight this epidemic.  Through these efforts, Molbio is committed to significantly reducing the TB burden in India and beyond.

Qure.ai – AI-Powered Breakthroughs in TB Detection

Qure.ai leverages artificial intelligence to enhance tuberculosis (TB) diagnosis in India. Their qXR solution analyzes chest X-rays to detect presumptive cases of TB, providing rapid results in just under a minute, significantly reducing diagnosis time. Additionally, their qTrack platform facilitates seamless patient management throughout the diagnostic and treatment process. Deployed across 95+ countries, their technology has impacted over 29 million lives so far, also targeting underserved communities. Both qXR and qTrack have been evaluated by the World Health Organization (WHO) and are CE-certified, reinforcing their reliability in TB screening and patient management. Collaborations with organizations like the India Health Fund and PATH aim to improve early TB detection and patient outcomes, particularly in underserved communities.

Lupin Limited – Advancing TB Treatment and Accessibility

Lupin Limited, with its goal to combat tuberculosis (TB), aims to be the largest global supplier of first-line anti-TB drugs globally. The company's commitment to providing affordable and innovative therapies is bolstered by its strategic partnerships, particularly in low- and middle-income countries. The collaborations, including those with the Global Alliance for TB Drug Development and the Indian government, play a crucial role in enhancing access to quality medicines at affordable prices, adopting a collaborative approach to public health.

In 2024-2025, Lupin has continued its commitment to combat tuberculosis by introducing new formulations, including a fixed-dose combination of Rifapentine and Isoniazid, to improve TB prevention and treatment. Lupin’s ongoing partnerships and innovative approaches are a testament to the unwavering vision of a TB-free world.

Cepheid – Transforming TB Diagnostics with Automation

Cepheid is dedicated to improving healthcare by pioneering molecular diagnostics that combine speed, accuracy, and flexibility. The company's GeneXpert® systems and Xpert® tests automate highly complex and time-consuming manual procedures, providing A Better Way for institutions of any size to perform world-class PCR testing. Cepheid’s broad test portfolio spans respiratory infections, blood virology, women’s and sexual health, TB and emerging infectious diseases, healthcare-associated infectious diseases, oncology, and human genetics. The company’s solutions deliver actionable results where they are needed most – from central laboratories and hospitals to near-patient settings.

As per the NTEP Report, in 2023 – over 63000 MDR-TB were Notified, Cepheid’s fight against Drug resistance TB Continues with Xpert MTB/XDR which enables rapid molecular DST. When combined with the frontline Xpert MTB/RIF Ultra test, it sets new standards by detecting mutations associated with resistance to isoniazid (INH), fluoroquinolones (FLQ), second-line injectable drugs (SLIDs), and ethionamide (ETH) in a single test. This assay was recommended and introduced in the Guidelines by NTEP.

ECHO India – Bridging Gaps in TB Knowledge and Care
 

ECHO India, established in 2008, is a pioneering not-for-profit organization transforming healthcare, education, gender, and livelihoods through its collaborative “Hub & Spoke” learning model. By connecting frontline workers with experts and resources, ECHO India enhances capacity-building and addresses disparities across sectors.

In support of the National TB Elimination Programme’s (NTEP) goal to eliminate TB, ECHO India partnered with the Central TB Division (CTD) and other National TB institutions including the National Institute for Tuberculosis and Respiratory Diseases (NITRD), Delhi, NIRT Chennai, State Tuberculosis Cells (STCs) and State TB Training and Demonstration Centres (STDCs). Through the ECHO model, ECHO has extended its reach to remote areas such as Kupwara, Baramulla, Ladakh, Lakshadweep, and the Northeast, where access to specialized medical care is limited. By connecting various categories of frontline workers with experts, we ensure access to the latest practices and protocols. A key feature of our model is case-based learning, allowing clinicians to present challenging cases and collaboratively find solutions. With over 100 hubs and 7 lakh+ attendances in TB alone, the ECHO Model with its "All Teach, All Learn" approach has become integral to the revamped NTEP, empowering healthcare providers to work towards a TB-free India.

 DeepTek – AI-Driven Lung Health Screening for TB

DeepTek’s AI-powered lung health screening solution offers a seamless, end-to-end approach, operating both online and offline to ensure accessibility in remote areas. It features a robust Patient Registration and Vulnerability Assessment System, while its advanced AI swiftly analyzes Chest X-rays, identifying TB Suspects within a minute. The solution helps in centralizing the data and gives analytics, enabling a data-driven public health strategy.

Beyond TB detection, it identifies 20+ chest pathologies, including pneumonia and other critical conditions. Deployed across 175+ sites, it has extended its reach to some of the most underserved regions. To date, over 2 million individuals have been screened using Genki, significantly impacting global lung health.

Backed by regulatory approvals, the solution is US FDA-cleared, CDSCO-approved, and ICMR validated. In Tamil Nadu, it has played a crucial role in increasing TB detection yield by 25x, significantly enhancing early diagnosis and intervention efforts.

IPE Global – Advancing TB Control Through Innovation
 

IPE Global stands at the forefront of tuberculosis (TB) control programs in India through comprehensive, multi-faceted interventions across the healthcare ecosystem. It provides technical support and policy advisory services, and pilots innovative initiatives to strengthen national and state TB programs. The organization also focuses on enhancing health systems through healthcare worker training, diagnostic network improvement, and digital health integration.

Its flagship initiative, Nikshay Patr, is the world's first Pay-for-Performance program designed to improve the nutritional status and treatment outcomes of TB patients. Led by IPE Global in partnership with the Central TB Division, the Government of Madhya Pradesh, and USAID, this program enabled evidence-based TB management.

Fostering public-private partnerships, IPE Global drives collaborative initiatives like the Corporate TB Pledge, which engages the corporate sector in TB prevention, through joint efforts with government and international development partners. The organization, through innovative financing approaches, also facilitates investments toward scale-up of market-based solutions to improve the accessibility and affordability of TB diagnostic services in underserved communities.
 

BD (Becton, Dickinson, and Company) – Strengthening TB Detection and Management

Becton Dickinson (BD) in India is actively involved in tuberculosis (TB) detection through innovative diagnostic solutions and strategic partnerships. They have developed the BACTEC MGIT automated mycobacterial detection system, which helps in detecting TB drug sensitivity, aiding in the fight against multi-drug resistant TB. Over 100 of these systems have been installed across India.

BD continues its commitment to TB elimination through initiatives like the TB Guardianship Program, launched to enhance knowledge exchange among healthcare professionals on effective TB diagnostic practices. Additionally, BD has introduced Project SANKALP, a catalytic effort aimed at strengthening TB detection and management by supporting patients throughout their treatment journey. This project facilitates early detection and timely management of TB cases, aligning with India's goal to eliminate TB by 2025. BD's efforts are part of the broader Corporate TB Pledge, supporting the National TB Elimination Program (NTEP) in India

Fighting Tuberculosis with Innovation: Premas Life Sciences and Uncoded Lead the Way

Uncoded by Premas Life Sciences is transforming drug-resistant TB detection with its tNGS Panel—a faster, more precise, and cost-effective solution. Backed by the WHO’s latest TB guidelines, this innovation enables rapid, high-accuracy screening and supports India’s fight against TB.
 

As India intensifies efforts to eliminate TB, Uncoded by Premas Life Sciences (PLS) is pioneering a breakthrough in drug-resistant TB (DR-TB) diagnostics. With the introduction of Amplicon-Based Targeted Gene Sequencing (tNGS) Panels, Uncoded aims to revolutionize TB detection by offering:

●    Faster & Cost-Effective Screening – Detects known drug resistance mutations with higher accuracy than conventional PCR-based assays.
●    Scalability & Accessibility – High-throughput testing for wider clinical adoption.
●    Direct DNA Compatibility – Eliminates the need for culture-based testing, reducing turnaround time.

Aligned with the WHO's latest TB guidelines, Uncoded’s approach ensures precise genetic insights, enabling clinicians to make informed treatment decisions and improve patient outcomes. Currently, PLS is collaborating with leading hospitals and research institutions to validate this cutting-edge solution.

By developing an India-specific diagnostic workflow, Uncoded strengthens the "Make in India" initiative, ensuring homegrown, high-quality molecular diagnostics. On this World TB Day, Uncoded reaffirms its commitment to fighting TB through innovation, precision, and purpose-driven healthcare solutions—because the future of TB diagnostics is faster, smarter, and genomics-driven.
    
Disclaimer: This feature highlights select organizations contributing to the fight against tuberculosis (TB). However, many other organizations are making significant strides in TB eradication but are not included in this list. Additionally, the order in which the organizations are presented does not reflect any ranking or level of impact.
 

The Indian Organization for Rare Diseases (IORD)

The Indian Organization for Rare Diseases (IORD) is a registered non-profit and a Ministry of Corporate Affairs-recognized CSR Implementing Agency advocating for rare disease patients in India. It envisions a future where these patients receive equal healthcare opportunities and focuses on policy development, awareness, and patient support. IORD educates medical professionals, assists in diagnosis, and facilitates treatment access. It also promotes research and global collaborations to improve care. Addressing awareness gaps, social stigma, and delayed diagnoses, IORD actively works to enhance healthcare policies and ensure better resources for rare disease patients across India.

Dystrophy Annihilation Research Trust [DART]

Dystrophy Annihilation Research Trust (DART) is India’s first research lab dedicated to Duchenne Muscular Dystrophy (DMD). Founded by RS Anand in 2012, it focuses on genetic-level treatments to slow or reverse DMD progression. The organization provides patient support, medical advisory services, rehabilitation assistance, and counseling for families. DART also raises awareness, promotes inclusion in education and employment, and collaborates with NGOs. Its R&D lab offers much-needed research within India, giving hope to affected families by ensuring access to critical interventions.

Cure SMA Foundation 

Cure SMA India is a nonprofit organization dedicated to supporting individuals with Spinal Muscular Atrophy (SMA), a rare genetic disorder causing progressive muscle weakness due to motor neuron degeneration. The NGO focuses on patient advocacy, early diagnosis, and access to life-saving treatments, without specifying treatment names. It provides medical assistance, rehabilitation support, and family resources while collaborating with researchers and policymakers to improve treatment availability and affordability. Through awareness campaigns and community engagement, Cure SMA India empowers individuals affected by SMA and advocates for improved healthcare policies in India

The Lysosomal Storage Disorders Support Society (LSD) The Lysosomal Storage Disorders Support Society (LSD) , established in 2010, is India's first and leading patient advocacy group dedicated to Lysosomal Storage Disorders (LSDs). A pan-India non-profit organization, it is managed by patients and their parents/caregivers, focusing on creating awareness among the public, physicians, and policymakers. LSDSS has achieved significant milestones by facilitating treatment options through international charitable access programs and state healthcare budgets. They have also played a pivotal role in the formulation of India's National Policy for Rare Diseases (NPRD). Their work areas include patient support, advocacy, awareness campaigns, and collaboration with national and international organizations to strengthen the patient voice and improve LSD awareness.

The Bharath MD Foundation

The Bharath MD Foundation, founded by mothers of children with Duchenne Muscular Dystrophy (DMD), is dedicated to support, advocacy, and awareness for affected families. It provides free genetic testing, medical and rehabilitation support, and educational resources to empower individuals with DMD. The foundation collaborates with researchers and policymakers to enhance treatment access and drive policy changes. Key initiatives focus on awareness campaigns, research partnerships, and expanding medical services. With a vision for improved care and inclusion, the organization continues to champion hope, resilience, and change for the DMD community in India.

The Atypical HUS foundation 

aHUS India is a dedicated support network for individuals affected by Atypical Hemolytic Uremic Syndrome (aHUS) in India. The organization focuses on patient advocacy, early diagnosis, treatment access, and community support. Recently, aHUS India has been working to connect Indian patients with global research efforts, ensuring access to the latest advancements in complement-inhibitor therapies. It has also been advocating for insurance coverage and government policy inclusion for aHUS treatments. Through awareness campaigns, patient guidance programs, and expert collaborations, aHUS India is striving to improve the quality of life for those battling this rare and life-threatening disease.

Mobility in Dystrophy (MIND) Trust  

Mobility in Dystrophy (MIND) Trust, founded in 2017, supports individuals in Kerala with Muscular Dystrophy (MD) and Spinal Muscular Atrophy (SMA) through 18 projects focused on awareness, education, skill development, rehabilitation, and research. Recognized for its efforts, MIND Trust received Kerala’s Best NGO Award (2021), N.S Hema Memorial 3rd position (2023), and the 12th FESCA Award (2024). The organization is dedicated to realizing ORIDAM, a holistic center providing rehabilitation, residential care, education, employment, and research to empower individuals with MD and SMA, fostering independence and self-sustainability while advancing innovative approaches for better management and support.

DATRI Blood Stem Cell Donors Registry

DATRI Blood Stem Cell Donors Registry is a not-for-profit organization committed to helping patients with life-threatening blood disorders -  such as leukemia, thalassemia, lymphoma, and aplastic anemia - by facilitating life-saving blood stem cell transplants.DATRI actively identifies and registers potential donors by raising awareness about stem cell donation. Through collaborations with hospitals, medical institutions, colleges, and corporates, it works to build a diverse and accessible donor database for patients in need.With a registry of over 5.7 lakh donors, DATRI has successfully facilitated more than 1,530 stem cell donations, offering patients battling blood disorders a second chance at life.As India’s largest unrelated blood stem cell donor registry, DATRI plays a pivotal role in saving lives through donation, advocacy, and continuous efforts to expand its life-saving impact.

 Indo US Organization for Rare Diseases

 "Indo US Organization for Rare Diseases is a non-profit organization dedicated to rare disease research, advocacy, and collaboration between India and the U.S. Their mission is to educate, empower, and advocate for patients globally, fostering diversity, equity, and inclusion in research. They focus on patient-centric education, awareness, training, and engagement aligned with the FDA’s patient-focused drug development paradigm. Indo US organization for rare diseases promotes global diversity in clinical trials, improves patient access to research, and collaborates on public health policies. By bridging stakeholders from India and the U.S., they aim to enhance patient outcomes, accelerate diagnostics and therapies, and address challenges faced by rare disease communities.”

 The Indian Society for Inborn Errors of Metabolism (ISIEM)

 The Indian Society for Inborn Errors of Metabolism (ISIEM), conceived in 2005 and registered as a society in 2012, is dedicated to improving awareness, diagnosis, and management of inherited metabolic disorders in India. Their core work areas include research, patient advocacy, physician training, and policy advocacy for better healthcare access. ISIEM organizes national and international conferences, workshops, and training programs to educate healthcare professionals on inborn errors of metabolism (IEM). ISIEM also publishes clinical guidelines & protocols on management , collaborates on newborn screening programs, and works towards making diagnostic and therapeutic facilities more accessible. ISIEM is known for pioneering efforts in metabolic disorder awareness and strengthening India's rare disease ecosystem.

Cystic Fibrosis India (CFI)

 Cystic Fibrosis India (CFI) is committed to improving the lives of individuals with Cystic Fibrosis (CF) through advocacy, support, and awareness. The organization works to ensure early diagnosis, access to treatment, and specialized care for CF patients across India. CFI provides medical assistance, nutritional guidance, and rehabilitation support, helping families navigate the challenges of this rare genetic disorder. By collaborating with doctors, researchers, and policymakers, CFI advocates for better healthcare infrastructure and treatment availability. Through education, outreach programs, and community initiatives, the foundation empowers patients and caregivers, striving to build a more informed and supportive environment for CF care.

Hereditary Angioedema Society of India (HAESI)

 The Hereditary Angioedema Society of India (HAESI) (https://www.haesi.in/) is a nonprofit organisation dedicated to increasing awareness and to promote knowledge about HAE amongst physicians; to improve quality of life of HAE patients and their families and bring better treatment options in India. The society has actively collaborated with global HAE networks over the last 4 years.  HAESI has organized several specialist training workshops to improve early detection and has been lobbying for the inclusion of HAE therapies in national health programs. The society also provides direct patient support, emergency treatment guidance, and counseling services. Through these efforts, HAESI is bridging the gap between medical advancements and patient accessibility in India.

 MSN Laboratories 

 MSN Laboratories has launched RADIUM, a dedicated division focused on rare diseases and unmet medical needs. As a global pharmaceutical leader, MSN offers over 60 solutions for rare conditions, reinforcing its commitment to innovation. With 25 advanced manufacturing facilities across India and the USA and Asia’s largest single-site integrated R&D center, MSN drives cutting-edge research for better medicines. The company’s diverse portfolio spans 475+ APIs and 350+ formulations across 40 therapeutic areas, serving over 50 million patients in 100+ countries. Through RADIUM, MSN continues to bring hope to rare disease patients worldwide, advancing access to life-saving treatments.

Akums Drugs and Pharmaceuticals

Akums Drugs and Pharmaceuticals, India’s largest CDMO, is revolutionizing rare disease treatment with innovation and accessibility. In line with its Rashtra Pratham approach, Akums has introduced a Room Temperature Stable Hydroxyurea Oral Suspension for Sickle Cell Disease (SCD), significantly improving affordability and access. Unlike global alternatives requiring cold storage and costing INR 77,000, Akums’ patented 2024 formulation is stable at room temperature and priced at just 1% of the global cost. With expertise across pharmaceuticals and advanced R&D, Akums continues to pioneer solutions for rare diseases, reinforcing its commitment to addressing critical healthcare challenges in India and beyond.

CENTOGENE

 With over 70 million people in India affected by rare diseases, timely diagnosis remains a critical challenge. CENTOGENE envisions reducing this diagnostic odyssey of undiagnosed and misdiagnosed cases through technological advancements. CENTOGENE is at the forefront of rare disease diagnostics, aiming to cure 100 rare diseases by 2031 through AI-driven bioinformatics, expansive data access, and continuous variant reclassification. Leveraging its Biodatabank - the world’s largest repository of real-world data on rare and neurodegenerative diseases- CENTOGENE is uncovering novel Gene-Disease Relationships. Additionally, early 2024 collaborations with the Laboratory of Human Genetics of Infectious Diseases and the Critical Path Institute have accelerated drug discovery. CENTOGENE’s groundbreaking research indicates that approximately 15% of Parkinson’s cases have a genetic link, reinforcing the need for genetic testing in patient care.

Disclaimer:

The information presented in this listicle, Rare Warriors: Organization Leading the Fight Against Rare Disease, is intended for informational purposes only. While we strive to provide accurate and up-to-date details about these organizations and their initiatives, we do not endorse or guarantee the efficacy of any treatments, services, or policies mentioned. Readers are encouraged to verify information through official sources and consult healthcare professionals for medical advice, diagnosis, or treatment.

AAYNA Clinic, helmed by the visionary Dr. Simal Soin has set a gold standard in personalized dermatology. They offer a range of advanced treatments such as anti-aging therapies, acne care, weight loss solutions, and hair restoration. They specialize in personalized services using cutting-edge technologies like Thermage, HydraFacial, and laser treatments. AAYNA is known for providing a premium experience with expert consultations and tailored beauty solutions. 

Every client receives a deeply tailored approach, making this clinic a trusted name among celebrities, professionals, and discerning individuals alike.

MedLinks is a premier skin and hair care clinic in Delhi and Gurgaon, specializing in treatments such as acne care, anti-aging therapies, hair restoration, and body contouring. With a team of experienced dermatologists and the latest technologies, MedLinks offers customized solutions to address various skin and hair concerns. 

They provide services like laser treatments, facials, liposuction, and rhinoplasty, aiming for effective and long-lasting results.

UnCover is a game-changer in the dermatology space, leveraging technology to make premium care accessible. With a straightforward and modern approach, UnCover has become a preferred choice for results-driven clients providing a seamless experience from online consultations to in-clinic treatments. Their services include laser hair removal, acne treatments, skin rejuvenation, hair restoration, and body contouring. The clinic uses advanced technologies such as GFC hair restoration, microneedling, and more.By blending digital accessibility with expert consultations, UnCover is redefining the dermatology experience. 

Alive Wellness Clinics, with over 25 years of experience, is a premier destination for skin, hair, and wellness treatments across Delhi and Punjab. Founded by Dr. Chiranjeev Chabbra , Alive Wellness offers services like anti-aging therapies, weight loss solutions, hair restoration, and skin rejuvenation, using cutting-edge technology for personalized care. With a focus on visible results and holistic wellness, The clinic provides a holistic approach to aesthetic care, helping clients look and feel their best.

The Ageless Clinic has built its reputation on providing solutions that emphasize longevity and sustainability. The Ageless Clinic offers advanced skin and aesthetic treatments, including laser therapies, body contouring, and anti-aging solutions. They focus on personalized care with state-of-the-art technology and international treatment standards. The clinic emphasizes patient confidentiality, ethical practices, and high-quality service. Their client-centric philosophy, combined with an unwavering commitment to high standards, has made The Ageless Clinic a standout in dermatology.